Efficacy of Cellular and/or Tissue-Based Product Applications on all Non-Pressure Injury Chronic Wound Types in a Medicare Private Practice Model

Background. This retrospective analysis is a derivative cohort study based on a prior retrospective investigation by this author group. Objective. To assess the effect of the number of cellular and/or tissue-based product (CTP) applications on healing outcomes and wound area reduction (WAR) rates in patients with chronic wounds of multiple etiologies. Methods. Data from a multicenter private wound care practice electronic health record database were analyzed for Medicare patients receiving CTPs from January 2018 through December 2023. Wound treatments were administered in nursing homes (4.77%), private clinics (80.11%), and home settings (15.65%), excluding hospital outpatient department settings. This retrospective analysis evaluated WAR and closure rates following each CTP application. Results. A total of 446 wounds were included in the analysis, comprising 123 diabetic foot ulcers (DFUs), 134 venous leg ulcers (VLUs), 62 surgical wounds, 51 trauma wounds, and 76 other chronic wounds. Significant reductions in average wound areas (cm²) were observed after completing the CTP application series (ie, ≤10 CTPs within 16 weeks) for all chronic wounds (P < .001). Further, there were more total healed wounds noted for the chronic surgical and trauma wounds compared with DFUs and VLUs. Conclusion. This retrospective real-world analysis of Medicare patients undergoing CTP therapy in conjunction with standard of care for chronic trauma and surgical wounds demonstrates substantial reductions in wound area following completion of a CTP application series. Findings from this study may guide governing bodies regarding CTP best practice recommendations in the treatment of chronic wounds of various etiologies.